# A Phase II Study of H021 Enteric-coated Tablets for Moderately to Severely Active Crohn's Disease

> **NCT07677514** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Jiangsu Carephar Pharmaceutical Co., Ltd.** · enrollment: 156 (estimated)

## Conditions studied

- Crohn's Disease

## Interventions

- **DRUG:** H021 Enteric-coated Tablets Low-dose Group
- **DRUG:** H021 Enteric-coated Tablets High-dose Group
- **DRUG:** Placebo Group

## Key facts

- **NCT ID:** NCT07677514
- **Lead sponsor:** Jiangsu Carephar Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-07-12
- **Primary completion:** 2026-10-12
- **Final completion:** 2027-11-12
- **Target enrollment:** 156 (ESTIMATED)
- **Last updated:** 2026-06-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07677514

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07677514, "A Phase II Study of H021 Enteric-coated Tablets for Moderately to Severely Active Crohn's Disease". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT07677514. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*